How Health Tech Is Personalizing Cancer Vaccines with mRNA

Episode 60 of The Digital Health Podcast explores how mRNA technology is being repurposed from COVID-19 vaccines to create personalized cancer immunotherapies. Lucas and Luna break down the science behind neoantigen prediction, the case of Moderna and Merck's melanoma trial showing 44% reduction in recurrence risk, and the logistical hurdles of manufacturing a custom vaccine for each patient within weeks. They discuss how AI-powered tumor sequencing enables this precision, the cost implications (around $100,000 per course), and what this means for the future of oncology. A concrete look at how digital health and genomics are converging to make individualized cancer treatment a reality. #mRNA #CancerVaccines #PersonalizedMedicine #Immunotherapy #Moderna #Merck #Melanoma #Neoantigen #TumorSequencing #AIHealth #DigitalHealth #Oncology #Biotech #Genomics #HealthcareAI #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo